

Did you know?
Nutricia now offers a
Diet-for-Life Care Coordinator
for your adult patients with PKU



Sharon Ernst, MPH, RDN, CSP, FAND, a metabolic dietitian with over 25 years of clinical experience is serving as our Diet-for-Life Care Coordinator.

To learn more, please email us at
DietforLife@nutricia.com

Nutricia Metabolics Webinar Series



3 PART WEBINAR SERIES:

**FEEDING &
DIET PRACTICES**

Part Three: Returning to Diet: Cognitive, affective, and motivational factors for people with PKU

Nutricia Metabolics Webinar Series



Part Three: Returning to Diet: Cognitive, affective, and motivational factors for people with PKU



June 28, 2017

Benjamin Goodlett, PhD

Metabolism Clinic, Department of Genetics and Genomics
Boston Children's Hospital

The opinions reflected in this Webinar are those of the speaker and independent of Nutricia North America.



Disclosures



- BioMarin NCT01889862. Receives salary support from Boston Children's Hospital for assisting in the clinical trial.
- Volunteer – Next Step, Inc. in Cambridge, MA
- Volunteer – HCU Network North America

Learning Objectives



- Understand the cognitive and affective (anxiety & depression) issues associated with adults with PKU when not following a low-PHE diet
- Discuss the importance of health behavior changes in line with individual's values
- Implement strategies to help patients overcome these challenges

PKU: A Very Brief Primer



- Phenylketonuria (PKU) is an inborn error of metabolism that results from mutations of the phenylalanine hydroxylase (PAH) gene.
- The incidence of PKU varies by country and ethnic group. In the United States the incidence is 1 in 13,500 to 19,000 births.
- Loss of PAH results in increased concentrations of phenylalanine in the blood and brain.

1. Scriver & Kaufman in Scriver, et al (eds). McGraw-Hill, 2001.
2. National Institutes of Health Consensus Development Panel. *Pediatrics* 2001, 972-82.

Mechanisms for PKU Pathogenesis




The mechanisms involved are still largely conjecture

- White matter disruption¹
- Large neutral amino acid (LNAA) transport disruption²

1. Mastrangelo et al. *Mol Genet Metab.* 2015, 171-177

2. de Groot, et al. *OJRD.* 2013, 8:133

Adherence to Diet is Difficult



Adapted from Walter JH, et al. *Lancet*. 2002;360:55-57.

PKU and Neurocognitive Functioning



1. High Phenylalanine (Phe) levels harm the brain
2. Traditional therapies do not completely protect individuals with PKU
3. Neurocognitive deficits make diet adherence more difficult

High PHE and Harm




Blood Phe and IQ are Correlated in Individuals with PKU

Observation period	Correlation between blood Phe and IQ	Lifetime IQ loss for each 100 $\mu\text{mol/L}$ (1.6 mg/dL) increase in blood Phe (IQ points)
Critical period (0–12 years old)	$r = -0.35^*$	1.3–3.1
Lifetime (all ages)	$r = -0.34^*$	1.9–4.1

* $p < 0.05$

Waisbren, et al. *Mol Genet Metab.* 2007;92:63-70.

Executive Deficits Across the Lifespan that May Worsen with Age



White DA, et al. *Neuropsychology*. 2001;15:221-229.

Areas of Executive Functioning



- Planning & Organization
- Response Inhibition
- Working Memory
- Problem Solving Strategies & Organizing information
- Processing Speed

Jahja et al. *Mol Genet Metab.* 2013, S57-S61

Waisbren, et al. *Mol Genet Metab.* 2007;92:63-70.

PKU and Affective Symptoms



- Depression and anxiety are common and linked to non-adherence
- The earliest descriptions of PKU noted psychiatric problems.
- Anxiety, stress, and depression are heightened by lifetime and concurrent metabolic levels


DiMatteo, Lepper, & Croghan. *Arch Intern Med.* 2000, 2101-2107

Følling. *Physiol Chem.* 1934, 169-176

Clacy, Sharman, & McGill. *J Dev Behav Pediatr.* 2014, 388-391



Psychiatric Diagnosis



Adapted from Pietz J, et al. *Pediatrics*. 1997;99:345-350.

How to Help? Build Identity Beyond Diagnosis



How to Help?

Connect Diet to Identity and Values



Motivation frequently changes and is often formed in the context of relationships.

1. **R**esist the righting reflex
2. **U**nderstand your patient's motivations
3. **L**isten with empathy
4. **E**mpower the patient

Rollnick, Miller, & Butler. Motivational Interviewing in Health Care. Guilford Press

How to Help?

Specific Communication Examples



- Open questions – Closed questions
- Using a ruler
- Assess importance and confidence
- “What next?” Immediate concrete step.
- Summarize the patient’s words into themes

Rollnick, Miller, & Butler. Motivational Interviewing in Health Care. Guilford Press

How to Help? Cognitive Functioning



- Assess ability/capability of adherence
 - Adaptive Functioning: Adaptive Behavior Assessment System (ABAS-3)
 - Executive Functioning: Behavior Rating Inventory of Executive Function (BRIEF)
- Address weak executive skills
 - Social support networks
 - Brief behavioral therapy
 - Stimulants used for ADHD?
 - Brain training websites?

How to Help?

Example of Building Executive Skills



1. Identify weak skills (e.g., emotion control)
2. Identify two to three recurring or repeating behaviors that indicate the deficit
3. Together, agree on a strategy and a cue to remind to use the strategy
4. Keep supports and supervision in place until mastery or success

Dawson & Guare. Smart but Scattered. Guilford Press

How to Help? Affective Problems



- Manage metabolic levels
- Social support
- Psychotherapy
 - Behavioral Activation
 - Acceptance and Commitment Therapy
- Psychotropic medication

Additional information



New England Genetics Collaborative

<https://www.gemssforschools.org/>

New England Metabolic Consortium of Metabolic Programs

<http://newenglandconsortium.org/>

References and Bibliography



Clacy, A., Sharman, R., & McGill, J. (2014). Depression, anxiety, and stress in young adults with phenylketonuria: associations with biochemistry. *Journal of Developmental & Behavioral Pediatrics, 35*(6), 388-391.

Dawson, P., & Guare, R. (2015). *The Smart But Scattered Guide to Success: How to Use Your Brain's Executive Skills to Keep Up, Stay Calm, and Get Organized at Work and at Home*. Guilford Publications.

de Groot, M. J., Hoeksma, M., Reijngoud, D.-J., de Valk, H. W., Paans, A. M., Sauer, P. J., & van Spronsen, F. J. (2013). Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis. *Orphanet journal of rare diseases, 8*(1), 133.

DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000). Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Archives of internal medicine, 160*(14), 2101-2107.

Finkelson, L., Bailey, I., & Waisbren, S. (2001). PKU adults and their return to diet: predicting diet continuation and maintenance. *Journal of inherited metabolic disease, 24*(4), 515-516.

Groselj, U., Tansek, M. Z., & Battelino, T. (2014). Fifty years of phenylketonuria newborn screening—A great success for many, but what about the rest? *Molecular genetics and metabolism, 113*(1), 8-10.

Jahja, R., Huijbregts, S. C., de Sonnevile, L. M., van der Meere, J. J., Bosch, A. M., Hollak, C. E., . . . de Vries, M. C. (2013). Mental health and social functioning in early treated phenylketonuria: the PKU-COBESO study. *Molecular genetics and metabolism, 110*, S57-S61.

References and Bibliography



Mastrangelo, M., Chiarotti, F., Berillo, L., Caputi, C., Carducci, C., Di Biasi, C., . . . Leuzzi, V. (2015). The outcome of white matter abnormalities in early treated phenylketonuric patients: a retrospective longitudinal long-term study. *Molecular genetics and metabolism*, 116(3), 171-177.

Pietz, J., Fätkenheuer, B., Armbruster, M., Esser, G., & Schmidt, H. (1997). Psychiatric disorders in adult patients with early-treated phenylketonuria. *Pediatrics*, 99(3), 345-350.

Scriver & Kaufman in Scriver, et al (eds). McGraw-Hill, 2001. National Institutes of Health Consensus Development Panel. *Pediatrics* 2001, 972-82

Rollnick, S., Miller, W. R., Butler, C. C., & Aloia, M. S. (2008). *Motivational interviewing in health care: helping patients change behavior*. New York, NY: Guilford

Waisbren, S. E., Noel, K., Fahrback, K., Cella, C., Frame, D., Dorenbaum, A., & Levy, H. (2007). Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. *Molecular genetics and metabolism*, 92(1), 63-70.

Walter, J., White, F., Hall, S., MacDonald, A., Rylance, G., Boneh, A., . . . Vail, A. (2002). How practical are recommendations for dietary control in phenylketonuria? *The Lancet*, 360(9326), 55-57.

White, D. A., Nortz, M. J., Mandernach, T., Huntington, K., & Steiner, R. D. (2001). Deficits in memory strategy use related to prefrontal dysfunction during early development: Evidence from children with phenylketonuria. *Neuropsychology*, 15(2), 221.

THANK YOU!



Questions?

Benjamin Goodlett, PhD

Benjamin.Goodlett@childrens.harvard.edu



Feedback, Please!

Certificate of Attendance



For those interested in obtaining a Certificate of Attendance:

1. For viewers of the Webinar: a link to a survey will pop-up as you exit.
2. If not, please go to: <https://www.surveymonkey.com/r/FeedingIEM>
3. Complete the survey and an event code will be available at the end of the survey.
4. Go to www.NutriciaLearningCenter.com and enter the event code. Your certificate will be automatically downloaded.

For question on this Webinar or Nutricia's products, please email:

NutritionServices@nutricia.com

or call:

1-800-365-7354 (option 2)

